Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: real life experience from the TReasure Registry
Authors' conclusion
Over 80% drug retention rate at 12th month of TCZ treatment in this real-world study was concordant with previously conducted TCZ clinical studies.
Study context
- Population
- DMARD-IR rheumatoid arthritis (RA) patients receiving tocilizumab (TCZ) as first-line biologic, TReasure Registry, Turkey (male/female 18.2%/81.8%; mean age 54.41 years)of 642 RA patients ever on TCZ
- Participants
- 258 patients
- Outcome
- Drug retention rate of TCZ (Kaplan-Meier)
Methodological detailsmulticentre, web-based registry, real-world, Kaplan-Meier analysis
- Multicentre
- Web-based registry
- Real-world
- Kaplan-Meier analysis
Main finding
As reported in the abstract
TCZ retention rate (Kaplan-Meier) · 12th, 24th, 36th and 60th months
Retention at 12th month
81.1%
Retention at 24th month
73.8%
Retention at 36th month
66.2%
Retention at 60th month
63.6%
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Discontinuation of TCZ | TCZ 22% |
| Treatment duration | TCZ median 15 (range 6–28) months |
- Discontinuation of TCZ — Discontinuation for primary or secondary inefficacy (main reason), n
- 29
Disease activity scores, decrease from baseline · 6th and 12th months
- Decrease from baseline significant
Original publication
Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: real life experience from the TReasure Registry. Clin Exp Rheumatol. Published 24 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →